PCYOX1L

Across TCGA pan-cancer cohorts, PCYOX1L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCYOX1L data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PCYOX1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCYOX1L expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where PCYOX1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.386	1.000	.002	50	view →
CCRCC	OS	Median	II,III,IV	0.228	0.979	.003	20	view →
LUAD	OS	Median	III,IV	0.239	0.656	.016	6	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
GBM	DFS	Median	All	0.806	0.628	.017	1	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.515	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCYOX1L–UCEC (DFS)

Open the UCEC breakdown →